Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 4, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2014-03-14
DOI
10.3389/fonc.2014.00052
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies
- (2013) CHIN-HSIAO TSENG et al. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS
- PPARγ signaling and metabolism: the good, the bad and the future
- (2013) Maryam Ahmadian et al. NATURE MEDICINE
- Differential activation of catalase expression and activity by PPAR agonists: Implications for astrocyte protection in anti-glioma therapy
- (2013) Nicholas K.H. Khoo et al. Redox Biology
- PPARγ agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells
- (2012) E Pestereva et al. BRITISH JOURNAL OF CANCER
- Genome-Wide Profiling of Peroxisome Proliferator-Activated Receptor in Primary Epididymal, Inguinal, and Brown Adipocytes Reveals Depot-Selective Binding Correlated with Gene Expression
- (2012) M. S. Siersbaek et al. MOLECULAR AND CELLULAR BIOLOGY
- On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells
- (2012) Owen D. Stechishin et al. NEURO-ONCOLOGY
- Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers
- (2012) Aurélien A. Sérandour et al. NUCLEIC ACIDS RESEARCH
- PPARγ Agonists Promote Oligodendrocyte Differentiation of Neural Stem Cells by Modulating Stemness and Differentiation Genes
- (2012) Saravanan Kanakasabai et al. PLoS One
- The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells
- (2011) Giovanni Vitale et al. BIOTECHNOLOGY ADVANCES
- Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits β-catenin-mediated glioma cell growth and invasion
- (2011) Zhengqiang Wan et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Peroxisome proliferator-activated receptor γ in bladder cancer: A promising therapeutic target
- (2010) Jose J Mansure et al. CANCER BIOLOGY & THERAPY
- Anterior-posterior patterning of neural differentiated embryonic stem cells by canonical Wnts, Fgfs, Bmp4 and their respective antagonists
- (2010) Marijke Hendrickx et al. DEVELOPMENT GROWTH & DIFFERENTIATION
- STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: A potential for targeted therapy?
- (2010) Claire Villalva et al. INTERNATIONAL JOURNAL OF CANCER
- Inverse association of PPARγ agonists use and high grade glioma development
- (2010) Christian Grommes et al. JOURNAL OF NEURO-ONCOLOGY
- β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells
- (2010) Xiangrong Liu et al. MEDICAL ONCOLOGY
- Cell-Specific Determinants of Peroxisome Proliferator-Activated Receptor Function in Adipocytes and Macrophages
- (2010) M. I. Lefterova et al. MOLECULAR AND CELLULAR BIOLOGY
- Unknown
- (2010) Maria Simula et al. MOLECULAR MEDICINE
- Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation
- (2010) Anne Bugge et al. PPAR Research
- PPARγ regulates LIF-induced growth and self-renewal of mouse ES cells through Tyk2-Stat3 pathway
- (2009) Caiqing Mo et al. CELLULAR SIGNALLING
- PPARγ and RXRγ ligands act synergistically as potent antineoplastic agentsin vitroandin vivoglioma models
- (2009) Alessio Papi et al. JOURNAL OF NEUROCHEMISTRY
- Neoplastic and Non-neoplastic Changes in F-344 Rats Treated with Naveglitazar, a γ-Dominant PPAR α/γ Agonist
- (2009) Gerald G. Long et al. TOXICOLOGIC PATHOLOGY
- PPARγ agonists inhibit growth and expansion of CD133+ brain tumour stem cells
- (2008) W Chearwae et al. BRITISH JOURNAL OF CANCER
- The cardiovascular safety of rosiglitazone
- (2008) Ramzi A Ajjan et al. Expert Opinion On Drug Safety
- Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
- (2008) Ronald A. Lubet et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More